Revised International Prognostic Scoring System (IPSS-R) for MDS
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Very low risk0–1.5
- Low risk1.5–3
- Intermediate risk3–4.5
- High risk4.5–6
The Revised International Prognostic Scoring System (IPSS-R) for MDS calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include cytogenetics. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Prognostic scoring for myelodysplastic syndromes: cytogenetics, blasts, hemoglobin, platelets, ANC.
Clinical Indication
The Revised International Prognostic Scoring System (IPSS-R) for MDS is indicated for bedside clinical practice to support Prognostic scoring for myelodysplastic syndromes: cytogenetics, blasts, hemoglobin, platelets, ANC.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
Points: cytogenetics 0-4, blasts 0-3, Hb 0/1/1.5, platelets 0/0.5/1, ANC 0/0.5
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| cytogenetics | string | Yes | Cytogenetic risk |
| bm_blasts | string | Yes | Bone marrow blasts |
| hemoglobin | string | Yes | Hemoglobin |
| platelets | string | Yes | Platelets |
| anc | string | Yes | ANC |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1.5 | Very low risk | Very low risk |
| 1.5–3 | Low risk | Low risk |
| 3–4.5 | Intermediate risk | Intermediate risk |
| 4.5–6 | High risk | High risk |
| 6–20 | Very high risk | Very high risk |
Evidence-Based References (EBM)
- Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
Related calculators
- DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis
- GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis
- Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+)
- DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis
- GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis